A Phase 1a/1b, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABX1100 in Normal Healthy Volunteers and Late-onset Pompe Disease Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABX 1100 (Primary)
Indications Glycogen storage disease type II
Focus Adverse reactions; First in man
Sponsors Aro Biotherapeutics

Most Recent Events

10 Apr 2025 Timeframe for primary endpoints has been changed from upto 16 weeks to upto 20 weeks
11 Feb 2025 According to an Aro Biotherapeutics media release, results from this study supporting the potential for quarterly dosing.
11 Feb 2025 Status changed from recruiting to completed, According to an Aro Biotherapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight